Product review · Updated September 30, 2026
La Roche-Posay Effaclar Medicated Cleanser: an acne label and a blackhead question
Two US label versions identify the medicated wash; their acne-use fields do not supply a measured blackhead or pore-appearance result.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
Effaclar Medicated Cleanser is a named salicylic-acid wash, but a search for blackheads asks more than whether a product is labeled for acne. The US records examined here identify the active ingredient and treatment purpose. They do not give a participant group or measured result specifically for visible pores.
The review compares a July 2025 label with a December 2023 record. Direct manufacturer product pages were unavailable during this review, so their current promotional wording is not reconstructed from other products or markets. The resulting account is a reading of the exact posted labels and their limits.
In this article
The July 2025 record is the starting point
The more recent US label identifies La Roche-Posay Effaclar Medicated Cleanser, with salicylic acid 2% and a gel code. Its product identifier is NDC 49967-402. The document says version 10 and has an effective date of July 8, 2025. That label date is separate from this review’s September 2026 source check.
This is useful product identity evidence. It tells us which recorded wash is being discussed rather than allowing the Effaclar range to stand in for an exact item. It does not tell us which container a retailer supplies, whether a reader has that version, or how that reader’s skin has changed. Those questions require evidence beyond a posted product record.
Acne treatment is a purpose, not a pore measurement
The label’s purpose and use concern acne treatment. No blackhead count or visible-pore measurement is specified in those use fields. That is a narrow observation about the document, not a claim that the cleanser can never affect a blackhead or that every kind of pore visibility is acne.
FDA’s Drug Facts explanation defines purpose as the action or category and uses as the conditions a medicine treats or prevents. These headings serve a different role from a clinical outcome table. The visible-pores-versus-blackheads guide helps frame the distinction before an acne-labeled wash is asked to answer a broader appearance question.
What the blackhead term adds
AAD describes a blackhead as an open comedo: a particular acne finding associated with material accumulating inside a pore. Its acne-signs account is general educational context, not evidence from testing Effaclar. It prevents the everyday phrase visible pores from being treated as a precise blackhead endpoint.
The current cleanser label still gives no blackhead-specific study summary in the reviewed use language. A useful product description can acknowledge the acne purpose while keeping that missing detail visible. It cannot turn a general category into a measured count. This leaves room for a clear question about which outcome was assessed, rather than assuming that an active percentage answers it.
The earlier record is a different version
The December 2023 record carries NDC 49967-023 and also identifies a salicylic-acid gel cleanser. It names the same 2% active and acne purpose. Those similarities are useful continuity, but the different identifiers and dates remain part of the evidence rather than disappearing into a single timeless formula.
FDA notes that OTC product ingredients, dosages or warnings can change and that similar names can accompany different ingredients. That labeling context supports version awareness; it does not prove why this particular record changed. The older label is not treated as a second clinical trial, as evidence that old stock remains available, or as an inspection of a bottle someone currently owns.
The base changes without a new pore claim
The complete inactive prose lists are not identical. The 2025 list includes sodium benzoate, while the 2023 list does not. Both separately name capryloyl salicylic acid. Its presence in an inactive list does not supply an additional declared salicylic-acid percentage or a measured pore result.
These are documentary differences, not a conclusion about which base performs better. We retain each declaration as written rather than blending them into a new list. The product-claims guide is relevant to that restraint. A formula can be accurately identified while the extent of any visible-pore change still remains unknown in the examined label fields.
A cleanser name does not erase the caution
Both labels retain a warning about irritation and dryness alongside use of another topical acne medication. The current warning belongs beside the product’s acne purpose. It is not a measured comfort score, nor does it establish how likely a particular person is to experience discomfort.
No application schedule or combination plan is supplied here. The relevant observation is that the label presents limitations as well as a use. Readers comparing the questions asked across products can continue to the Neutrogena cream-cleanser review and Paula’s Choice liquid review. These links open separate records; they do not confer Effaclar’s label evidence on another item.
A bounded conclusion from two posted labels
The two US records provide meaningful identity, active, base and version evidence. They support calling the item a medicated acne cleanser with a declared 2% salicylic active. They do not supply the direct current manufacturer page, an underlying trial report or a selected pore-appearance endpoint.
Those missing records are not replaced with regional promotional language or nearby Effaclar products. The format comparison provides broader navigation among washes and other forms. For this exact cleanser, the clear distinction is between a documented acne-use label and the additional evidence needed to describe a particular blackhead or visible-pore outcome. The posted purpose is useful, but it is not that additional evidence.
Sources behind this reading
- L’Oreal Effaclar Medicated Cleanser: July 8, 2025 US SPL, NDC 49967-402 ↗Official posted US product-label record; exact date, NDC and version scope · Checked September 30, 2026
- L’Oreal Effaclar Medicated Cleanser: December 31, 2023 US label, NDC 49967-023 ↗Official posted US product-label record; exact date, NDC and version scope · Checked September 30, 2026
- FDA: reading an OTC Drug Facts label ↗Regulator consumer labeling guidance · Checked September 30, 2026
- American Academy of Dermatology: Acne signs and symptoms ↗Clinical category explanations; not an image-based assessment · Checked September 30, 2026